[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epithelial-tumors-malignant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epithelial-tumors-malignant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100623717","evaluation-of-an-epcam-targeted-radiotracer-in-epithelial-tumors-100623717",false,"NCT07400263","Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors","A Prospective Clinical Study of an EpCAM-Targeted Radiotracer for Molecular Imaging of Epithelial Tumors","Inclusion Criteria:\n\n1. Patients with diagnosed or suspected tumors visiting the hospital between January 2026 and December 2026, who are scheduled for pathological biopsy or surgical treatment within 2 months.\n2. Age \\> 18 years, regardless of gender.\n3. Adequate organ and bone marrow function as defined by the following laboratory values:\n\n   * Hematology: WBC ≥4.0×10\\^9\u002FL or ANC ≥1.5×10\\^9\u002FL; PLT ≥100×10\\^9\u002FL; Hemoglobin ≥90 g\u002FL.\n   * Liver Function: Total bilirubin ≤1.5× ULN; ALT and AST ≤2.5× ULN (or ≤5× ULN if liver metastases are present).\n   * Renal Function: BUN ≤1.5× ULN; Serum Creatinine (SCr) ≤1.5× ULN.\n4. Normal cardiac function.\n5. Expected life expectancy ≥12 weeks.\n6. Presence of at least one measurable target lesion according to RECIST v1.1 criteria.\n7. Patients recommended by clinicians to undergo PET\u002FCT examination for tumor diagnosis and staging.\n8. Women of childbearing potential must have a negative pregnancy test within 7 days prior to the examination. Male and female patients of reproductive age must agree to use effective contraception during the study and for at least 3 months after the examination.\n9. Voluntarily participate in the study, demonstrate full understanding of the protocol, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe laboratory abnormalities, including significant impairment of hepatic or renal function, or severe hematological dysfunction.\n2. History of allergic diseases.\n3. Patients planning for pregnancy during the study period.\n4. Pregnant or lactating women.\n5. Inability to maintain a supine position for at least 30 minutes.\n6. Patients with claustrophobia or other diagnosed psychiatric disorders that may interfere with compliance.\n7. Any other condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the evaluation of the study results.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this prospective, single-arm clinical trial is to evaluate the imaging performance and safety of an EpCAM-targeted radiotracer, \\[68Ga\\]Ga-PN-EpC1, in patients with epithelial tumors.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity of \\[68Ga\\]Ga-PN-EpC1 PET\u002FCT for detecting EpCAM-positive tumor lesions?\n* How does the radiotracer uptake correlate with EpCAM expression assessed by immunohistochemistry?\n* Is \\[68Ga\\]Ga-PN-EpC1 safe and well tolerated when administered for PET\u002FCT imaging in patients with epithelial tumors? Participants will undergo \\[68Ga\\]Ga-PN-EpC1 PET\u002FCT imaging prior to tumor biopsy or surgical resection. Imaging findings will be analyzed and compared with histopathological results and standard imaging assessments. Safety will be evaluated by monitoring adverse events following radiotracer administration.",[26],"Epithelial Tumors, Malignant","RECRUITING","2026-03-24",{"date":30,"type":31},"2026-03-30","ACTUAL",{"date":33,"type":31},"2026-03-04",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"Peking University People's Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":39},"100450129","early-phase-1-assessment-of-the-safety-and-tolerability-of-ex-vivo-next-generation-neoantigen-selected-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-epithelial-tumors-and-immune-checkpoint-blockade-icb-resistant-solid-tumors-100450129","NCT05141474","Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors","A Phase I Study to Assess the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors","NEXTGENTIL-ACT","Inclusion Criteria in the pretreatment phase:\n\n1. Patients must have histologically or cytologically proven metastatic or unresectable solid tumors. The disease must have progressed to at least one standard therapy (including at least one prior line with ICB for the group of patients with tumors where ICB is approved), or the patient is unable\u002Funwilling to receive standard therapy or no standard therapy exists for a particular disease.\n2. Patients must have at least one adequate lesion (primary tumor or metastasis) for resection or biopsy for TIL generation with minimal morbidity (preferentially using imaging-guided minimally invasive procedures).\n\n   Note: If this lesion was previously irradiated, the lesion must have demonstrated progression prior to resection\u002Fbiopsy.\n3. Patient must be at least 18 years old at the tissue procurement visit.\n4. Patient must understand and voluntarily sign an informed consent document before any study-related assessments\u002Fprocedures being conducted.\n5. Patient must be able and willing to comply to the study visit schedule and protocol requirements.\n6. Patients must have a clinical performance of Eastern Cooperative Oncology Group 0 or 1.\n7. Patients are considered medically fit enough by investigator to undergo all study procedures and interventions.\n8. Patients with documented left ventricular ejection fraction (LVEF) of ≥45%.\n9. Patients with documented forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) ≥50% tested by a pulmonary function test.\n10. Patients must be seronegative for HIV antibody (patients who are HIV seropositive may be less responsive and more susceptible to toxicities related to this experimental treatment since they may have a decreased immune competence).\n11. Patients must be seronegative for active hepatitis B (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test), and seronegative for hepatitis C (HCV) antibody. Patients with a history of hepatitis B virus (HBV) infection and having a negative HBsAg test and a positive antibody to hepatitis B surface antigen (HBsAg) are eligible. Patients with the hepatitis C antibody test positive are eligible only if tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n12. Life expectancy ≥6 months.\n13. Patients who are of childbearing potential (postmenarcheal who has not reached a postmenopausal state and has not undergone surgical sterilization) or have partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 6 months after the last dose of IL-2.\n\nInclusion Criteria in the treatment phase:\n\n1. The disease must have progressed to the last standard therapy, including at least one prior line with ICB for the group of patients with tumors where ICB is approved, and no subsequent approved therapy is available, or the patients are unable\u002Funwilling to receive standard therapy, or no standard therapy exists for a particular disease.\n2. Patients must have a remaining measurable disease as defined by RECIST v. 1.1 criteria following tumor resection\u002Fbiopsy for NEXTGEN-TIL manufacturing.\n\n   Note: Lesions previously irradiated should not be selected as target lesions unless there has been demonstrated progression in those lesions.\n3. Patients must understand and voluntarily sign an informed consent document before any study-related assessments\u002Fprocedures being conducted.\n4. Patients must be able and willing to comply with the study visit schedule and protocol requirements.\n5. Patients must have a clinical performance of Eastern Cooperative Oncology Group (ECOG) 0 or 1.\n6. Patients are considered medically fit enough to undergo all study procedures and interventions and adequate hematological, renal and hepatic functions defined by:\n\n   1. Haemoglobin ≥9.0 g\u002FdL.\n   2. An absolute neutrophil count ≥1000\u002Fmm3 without the support of filgrastim.\n   3. Platelets ≥ 100 x10⁹ \u002Fmm3.\n   4. PT and aPTT ≤1.5 x upper limit of normal (ULN, unless receiving therapeutic anticoagulation). Subjects receiving therapeutic anticoagulation (such as low-molecularweight heparin or warfarin) should be on a stable dose.\n   5. AST or ALT ≤3 x ULN. Patients with liver metastases must have AST and ALT ≤5.0 x ULN.\n   6. Total bilirubin \\\u003C2 mg\u002FdL. Patients with Gilbert's Syndrome must have a total bilirubin ≤3.0 mg\u002FdL.\n   7. Serum creatinine \\\u003C1.5 mg\u002FdL or measured creatinine clearance ≥50 ml\u002Fmin calculated using the Cockcroft-Gault glomerular filtration rate estimation: (140 - age) × (weight in kg) × (0.85 if female)\u002F72 × (serum creatinine in mg\u002FdL).\n7. Patients must be seronegative for HIV antibody.\n8. Patients must be seronegative for active hepatitis B (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test), and seronegative for hepatitis C antibody. Patients with a history of hepatitis B virus (HBV) infection and having a negative HBsAg test and a positive antibody to hepatitis B surface antigen (HBsAg) are eligible. Patients with the hepatitis C antibody test positive are eligible only if tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n9. Life expectancy ≥3 months.\n10. Patients who are of childbearing potential (postmenarcheal who has not reached a postmenopausal state and has not undergone surgical sterilization) or have partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 6 months after the last dose of IL-2.\n11. Female participants: a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    1. Women of non-childbearing potential (WONCBP).\n    2. Women of childbearing potential (WOCBP), who:\n\n    i. Agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C1% per year from screening until 6 months after the infusion of the NEXTGEN-TIL product. Examples of contraceptive methods with a failure rate of \\\u003C1% per year include bilateral tubal occlusion, male sterilization, and copper intrauterine devices.\n\n    ii. Have a negative pregnancy test (blood) within one week before the first study treatment administration (applicable to premenopausal women and women ≤2 years after the start of menopause (menopause is defined as amenorrhea for \\\u003C2 years).\n12. Male Participants: during the treatment period and for at least 2 months after the last dose of study treatment, agreement to:\n\n    1. Remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom or a contraceptive method that result in a failure rate of \\\u003C1% per year, with partners who are WOCBP.\n    2. Refrain from donating sperm during the study.\n    3. Inform if his partner gets pregnant during this time.\n13. Any toxicity related to prior systemic therapy must have recovered to grade 1 or less according to NCI-CTCAE v5.0 at least 4 weeks before treatment enrollment, except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy, and Grade ≤2 peripheral neuropathy.\n\n    Note: Other Grade 2 AEs that are deemed clinically insignificant by treating physician and in consultation with Medical Monitor are permitted.\n14. Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.\n\nExclusion Criteria (any phase):\n\n1. Patients with symptomatic and\u002For untreated brain metastases. Note: Patients with definitively-treated brain metastases will be considered for enrollment after discussion with Medical Monitor; if, prior to the start of NMA-LD the patient is clinically stable for ≥3 months, there are no new brain lesions via magnetic resonance imaging (MRI) post-treatment, and the patient does not require corticosteroid treatment \\>10 mg prednisone or equivalent per day.\n2. Patients with leptomeningeal carcinomatosis.\n3. Patients with an active concurrent or history within the past 3 years of invasive malignancy, except for non-melanoma skin cancer, cervical and bladder carcinoma in situ, good prognosis ductal carcinoma in situ of the breast, or prostate carcinoma that is in remission under androgen deprivation therapy for \\> 2 years. Other exceptions may apply and require discussion between the Investigator and the Medical Monitor.\n4. Patients with an active systemic infection requiring anti-infective treatment within 14 days before preparative lymphodepleting therapy.\n5. Patients with active hepatitis B or hepatitis C.\n6. Patients with active autoimmune disease requiring immunosuppressive treatments.\n7. Patients with a history of organ or bone marrow transplantation.\n8. Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).\n9. Patients requiring regular treatment with steroids at a dose higher than prednisone 10 mg\u002Fday (or equivalent).\n\n   Note: use of inhaled, topical steroids and use of systemic physiologic corticosteroid replacement therapy are permitted.\n10. Patients with current or history within the last 6 months, as determined by the Investigator, of clinically significant, progressive, and\u002For uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastroenterological or neurological disease.\n11. Patients with a history of coronary revascularization or ischemic symptoms.\n12. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin)\n13. Patients with allergies to any of the compounds included in any of the treatment products.\n14. Patients with contraindications for cyclophosphamide, fludarabine and IL-2 at per protocol doses.\n15. Patients who have received any approved anti-cancer cytotoxic, anti-angiogenic and ICB therapy including radiotherapy within 4 weeks before preparative lymphodepleting therapy. Exception: palliative radiotherapy for bone metastasis \\>2 weeks before preparative lymphodepleting therapy, denosumab, bisphosphonates, androgen deprivation therapy for prostate cancer and hormonal therapy for breast cancer.\n16. Patients who have received any non-cytotoxic drug and molecular targeted therapy within 4 weeks before preparative lymphodepleting therapy (or within five half-lives of the investigational product, whichever is shorter).\n17. Patients who have received any investigational agent within 4 weeks before preparative lymphodepleting therapy (or within five half-lives of the investigational product, whichever is shorter).\n18. Patients who have received a live, attenuated vaccination within the 4 weeks before lymphodepleting therapy.\n19. Patients who have undergone major surgery in the previous 3 weeks before lymphodepleting therapy.\n20. Patients who have previously received any investigational cell or gene therapies.\n21. Women of childbearing potential who are pregnant or breastfeeding.\n22. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.",{"count":49,"type":20},10,[51],"EARLY_PHASE1","Background:\n\nThe presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead to remarkable antitumor responses supports that lymphocytes play a critical role in cancer immunity.\n\nAdoptive cell therapy using tumor-infiltrating lymphocytes product (TIL-ACT) is a well-established combination therapy currently under study in several world reference centers, using an autologous cell product without genetic modifications. This cell product consists of tumor-infiltrating lymphocytes (TIL), which are collected from the patient and expanded in the lab under specific conditions to enhance its antitumoral efficacy before reinfusion in the same patient. However, this cell product alone does not achieve adequate efficacy, and a combination of both previous non-myeloablative lymphodepleting (NMA-LD) chemotherapy and subsequent cytokine therapy (specifically IL-2) is needed to support the expansion of the infused cells.\n\nThe investigators hypothesize that TILs enriched for neoantigen recognition are superior to unselected TILs at mediating tumor regression in patients with epithelial tumors and even other solid tumors where immune checkpoint blockade (ICB) is approved and used as part of standard therapy. The investigators propose to manufacture a T-cell product composed of TILs that are selected based on their ability to recognize patient-specific neoantigens and to use these to treat patients with metastatic, refractory, epithelial cancers, as well as ICB-resistant solid tumors. Furthermore, it also proposed to study the tumor and T cells at baseline and after treatment to investigate whether specific phenotypic and functional traits may be associated with clinical outcome.\n\nPrimary objective:\n\nTo evaluate the safety and the tolerability of ex vivo next generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) in patients with metastatic or unresectable epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors.\n\nSecondary objectives:\n\n* To determine the success in producing active specific TILs from our target patients.\n* To evaluate the initial clinical activity of the NEXTGEN-TIL products in our target patients.",[26,54],"Malignant Solid Tumor",[56,57,58],"Immune checkpoint blockade resistant tumors","Tumor-infiltrating Lymphocyte","Adoptive Cell Therapy","2024-11-06",{"date":61,"type":31},"2024-11-07",{"date":63,"type":31},"2021-10-28",{"date":65,"type":20},"2027-01-01",{"name":67,"class":38},"Vall d'Hebron Institute of Oncology",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100513712","phase-1-study-of-mt-302-in-adults-with-advanced-or-metastatic-epithelial-tumors-100513712","NCT05969041","Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","MYE Symphony","Inclusion Criteria:\n\n1. Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed.\n2. Histologically proven, metastatic or advanced epithelial cancer including the following cancer types:\n\n   1. Urothelial\n   2. Cervical\n   3. Ovarian epithelial\n   4. Triple-negative breast\n   5. HR+\u002FHER2- breast\n   6. Pancreatic ductal adenocarcinoma\n   7. Gastric adenocarcinoma\n   8. Esophageal carcinoma\n   9. Non-small cell lung\n   10. Colorectal\n3. Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy.\n4. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.\n6. Life expectancy of \\> 12 weeks.\n7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%.\n8. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval \\\u003C 450 msec in males and \\\u003C 470 msec in females (\\\u003C 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval.\n9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry.\n10. Adequate organ function as defined by laboratory values at Screening.\n11. Willing and able to provide written informed consent.\n12. Willing to perform and comply with all study procedures including undergoing study-related biopsies and attending clinic visits as scheduled.\n13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment.\n14. Men and WOCBP must be willing to practice a highly effective method of contraception.\n\nExclusion Criteria:\n\n1. Known active CNS metastasis and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention.\n2. Pregnant or nursing women.\n3. Must be \\> 28 days beyond major surgery, including hepatectomy or joint replacement.\n4. Prior allogeneic bone marrow transplantation or solid organ transplant.\n5. Spinal cord compression not definitively treated with surgery and\u002For radiation.\n6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n7. Any acute illness including fever (\\> 100.4° F or \\> 38° C) within 7 days prior to Day 1\n8. Active systemic bacterial, fungal, or viral infection within 7 days prior to Day 1. Participant cannot have tested positive for COVID-19 within 7 days prior to Day 1.\n9. Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV).\n10. Other primary malignancies, except:\n\n    1. Adequately treated basal cell or squamous cell carcinoma\n    2. In situ carcinoma of the cervix or bladder, treated curatively and without evidence of recurrence for at least 2 years prior to the study, or\n    3. A primary malignancy which has been completely resected and in complete remission for at least 2 years\n11. History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n12. Prior grade \\> 3 immune-related AEs such as pneumonitis, colitis, hepatitis, nephritis; prior dermatitis and endocrinopathies are allowed provided corticosteroids are no longer required and endocrine-replacement therapy is stable and discontinued from prior therapy.\n13. Active autoimmune disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year.\n14. History of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious active arrhythmias or other clinically significant cardiac disease within 12 months of enrollment.\n15. Toxicity from previous anti-cancer therapy defined as toxicities (other than alopecia, or laboratory values listed above) not yet resolved to NCI CTCAE v5.0 Grade ≤ 1 or baseline. Participants with chronic Grade 2 toxicities (eg, peripheral neuropathy, laboratory values) may be eligible per the discretion of the Investigator and Medical Monitor.\n16. Has received:\n\n    1. Radiotherapy within 2 weeks of first administration of MT-302\n    2. Cytotoxic chemotherapy for treatment of the primary malignancy within 28 days or 5 half-lives, whichever is shorter, of administration of MT-302\n    3. Immune therapy for primary malignancy (eg, monoclonal antibody therapy, checkpoint inhibitors) within 28 days or 5 half-lives, whichever is shorter of first administration of MT-302\n    4. Targeted therapies for primary malignancy within 28 days or 5 half-lives, whichever is shorter, of first administration of MT-302\n    5. Anti-cancer vaccine within 12 weeks of first administration of MT-302\n    6. COVID-19 mRNA vaccine within 6 weeks of first administration of MT-302\n17. Has received a live vaccine ≤ 6 weeks prior to first administration of MT-302\n18. Has received packed red blood cells or platelet transfusion within 2 weeks prior to first administration of MT-302\n19. History of an allergic reaction to any of the excipients\n20. Enrollment in another interventional clinical trial within 28 days or 5 half-lives of the drug, whichever is shorter, of first administration of MT-302\n21. Any other condition that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements.",{"count":77,"type":20},48,[79],"PHASE1","MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.",[26],[83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100],"Urothelial cancer","Cervical cancer","Ovarian epithelial","Triple-negative breast cancer","HR+\u002FHER2- breast cancer","Pancreatic ductal adenocarcinoma","Gastric adenocarcinoma","Esophageal carcinoma","Non-small cell lung cancer","Colorectal cancer","TROP-2 expressing tumors","MT-302","Anti-TROP-2 chimeric antigen receptor","Myeloid cells","Monocytes","Chimeric Antigen Receptor (CAR)","mRNA","Lipid nanoparticle (LNP)","2024-01-16",{"date":103,"type":31},"2024-01-18",{"date":105,"type":31},"2023-08-02",{"date":107,"type":20},"2028-08-31",{"name":109,"class":110},"Myeloid Therapeutics","INDUSTRY",6]